Emerging PDE4 Inhibitors for Psoriasis and Inflammatory Disorders

Phosphodiesterase-4 (PDE4) enzymes regulate intracellular cyclic adenosine monophosphate (cAMP) levels in immune and inflammatory cells, thereby controlling cytokine production and immune activation. Dysregulation of the cAMP–PDE4 pathway contributes to inflammatory and immune-mediated diseases such as psoriasis, psoriatic arthritis, and atopic dermatitis. PDE4 inhibition elevates cAMP, activates protein kinase A, and suppresses NF-κB–mediated cytokine expression, resulting in anti-inflammatory effects. Despite early challenge s due to systemic adverse effects, recent advances (2022–2025) in topical and isoform-selective PDE4 inhibitors—such as apremilast, roflumilast, crisaborole, and difamilast—have improved efficacy, tolerability, and local targeting. Novel modalities including PDE4 degraders and dual- target inhibitors promise further refinement of this therapeutic class. This review provides an integrated appraisal of the pharmacologic mechanisms, clinical outcomes, and translational innovations in PDE4 inhibition, highlighting its evolving role as a safe, effective, and convenient alternative or complement to biologic therapies for psoriasis and related inflammatory disorders.